Connect with us

Business

5 Things To Know About The Endocannabinoid System

Published

on

So far, preliminary studies have shown that this system plays a significant role in maintaining health and well-being.

So little is known about  the largest receptor system in the human body which is the endocannabinoid system (ECS). Most sources indicate that the ECS was discovered barely three decades ago, in 1988.

Since then, scientists from around the world have made progressive discoveries about this dynamic system and its significance in health and disease.

The number of published studies and articles on the ECS have spiked significantly in the last decade spurring a growth in public interest in the subject. There are even suggestions that this “ seemingly abstruse” system could indeed be the most important system in the human body, given its large influence. Robert Mechoulam who is considered as a founding father of medical cannabis had this to say about the ECS.

“Two eminent scientists said that the endocannabinoid system is involved in essentially all human disease. This is a very strong statement, but it seems to be correct.”

Here are five things to know about the endocannabinoid system.

The ECS Is Made up of Three Primary Components

From what science has revealed so far, the ECS is made up of three primary components that are spread throughout the central and peripheral nervous system; endocannabinoids (ligands), endocannabinoid receptors, and endocannabinoid enzymes (synthesizing and degrading). The endocannabinoids are synthesized by enzymes in the system and interact with endocannabinoid receptors to produce certain effects in the body. Once they have finished their role, they are degraded and removed from the system. The ECS has been described as a “lipid signaling system.”

The ECS has two types of receptors which are CB1 and CB2. CB1 receptors are abundant in the central nervous system while CB2 receptors are abundant in immune cells. The primary endocannabinoids that have been identified are anandamide (bliss molecule) and 2-AG.  Anandamide is degraded by the enzyme FAAH while 2-AG is degraded by MAGL.

The ECS Is Present in Both Vertebrates and Invertebrates

Earlier on, it was believed that the ECS was only present in animals that have a backbone aka mammals. It has now emerged that invertebrates such as leeches and mollusks. It is however more pervasive in mammals.

The ECS Maintains Homeostasis in the Body

The ECS is a “regulatory” system that is involved in various important functions in the body. The primary role of the ECS is to maintain a state of homeostasis or physiological balance in the body. Terms such as endocannabinoid tone have emerged and are used to describe the overall state of the ECS in terms of the density and function level of its components.

When the ECS senses an imbalance, it triggers a cascade of events along signaling pathways to restore balance. For example, when the body temperature is too high, the ECS will trigger mechanisms to ensure that temperature is restored to normal parameters. The ECS is involved in regulating the following functions:

  • Pain
  • Sleep
  • Hunger
  • Metabolism
  • Hormonal function
  • Reproduction
  • Memory
  • Nausea and vomiting
  • Immunity
  • Moods

The ECS has an extensive network of receptors that are spread out in almost every part of the body. ECS receptors are highly concentrated on the skin which is the largest organ in the body. This wide network of receptors support the far reaching effects of the ECS.

Are You Endocannabinoid Deficient? Here's How To Tell
Photo by Zohre Nemati via Unsplash

Clinical Endocannabinoid Deficiency May Trigger Chronic Disease

The body may in some cases have a deficiency of endocannabinoids. This state which is described as clinical endocannabinoid deficiency syndrome (CECD) has been linked to some chronic conditions. One study that investigated the concept of CECD found that it could be the underlying trigger for chronic and treatment resistant conditions including migraines, irritable bowel syndrome, and fibromyalgia. The researchers further suggested that this could possibly explain how cannabis provides benefits for these conditions.

Phytocannabinoids in Cannabis Interact With the ECS

The cannabis plant has hundreds of bioactive molecules mostly made up of phytocannabinoids and terpenes. Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most investigated phytocannabinoids. Scientists have discovered that phytocannabinoid are able to mimic the actions of endocannabinoids that are produced naturally in the body. Hence, they are able to support the role of the ECS in maintaining homeostasis. This forms the basis of medical cannabis.

THC primarily binds to CB1 receptors in the brain. Alongside providing therapeutic benefits THC also causes psychoactive effects by altering the state of the mind to induce euphoria. CBD interacts indirectly with both the CB1 and CB2 receptors. Because it does not bind to the CB1 receptors, it does not cause psychoactive effects.

medical marijuana
Photo by simpson33/Getty Images

The ECS Forms the Basis For Medical Cannabis

Medical cannabis has gained significant traction in the last decade due to discoveries in science about the role of the ECS and how cannabis can influence this system. To date, 37 states have legalized medical cannabis programs that allow patients to access cannabis-based treatments.

Here are some of the conditions that have been approved for medical cannabis treatments in the US:

  • Cancer
  • Neuropathic pain
  • Multiple Sclerosis
  • HIV/AIDS
  • Diabetes
  • Multiple Sclerosis
  • Epilepsy
  • Crohn’s disease
  • Alzheimer’s disease
  • Joint degeneration
  • Nausea and vomiting in terminal illness
  • Anxiety
  • Depression
  • Sleep disorders
  • Mood disorders

Medicinal cannabis may also be used as adjuvant therapy to improve the efficacy of other drugs. For example, patients who are on opioids for pain management can use medicinal cannabis to reduce the amount of opioids that they are taking. This also has a positive impact on opioid-related side effects.

The ECS is still being studied and there is a lot that remains unknown about this system. So far, preliminary studies have shown that this system plays a significant role in maintaining health and well-being.  It is also clear that phytocannabinoids from cannabis have far reaching effects on the ECS, which forms the basis for medical cannabis.

Source: https://thefreshtoast.com/cannabis/5-things-to-know-about-the-endocannabinoid-system/

Business

Alleged Crores Pharma Scam Mastermind Arrested from Surat

Published

on

By

After evading law enforcement for nearly 13 years, an accused linked to a large-scale pharmaceutical fraud case has been arrested by Delhi Police from Surat, Gujarat. The suspect is alleged to have orchestrated a series of financial scams involving fake identities, forged documents, and dishonoured cheques used to procure high-value pharmaceutical raw materials.

Authorities say the accused, identified as Himmat Singh Lodha, is believed to have defrauded multiple pharmaceutical companies in Delhi of goods worth approximately ₹98 lakh before disappearing and remaining underground for years.

Fake Business Deals and Dishonoured Cheques Used in Fraud

Investigators claim the accused posed as a legitimate pharmaceutical trader and placed bulk orders for expensive drug ingredients, offering post-dated cheques as payment security.

In one documented case from 2013, he allegedly obtained around 550 kilograms of Gliclazide, a diabetes-related pharmaceutical ingredient, valued at over ₹26 lakh. When suppliers attempted to encash the cheques, they were reportedly returned with the remark “account closed.”

Following the transaction, the accused allegedly vacated his office and rented residence and disappeared without settling payments. He was later declared a proclaimed offender in 2016 after repeatedly failing to appear before court proceedings. Authorities had also issued a reward for information leading to his arrest.

Multiple Identities and Repeated Fraud Pattern

Police investigations further link the accused to another cheating case dating back to 2012, where he allegedly used a fake identity, “Kailash Jain,” to obtain a large consignment of Ambroxol HCL, a pharmaceutical compound used in cough medications. The value of that consignment was estimated at around ₹72 lakh.

Officials believe the accused followed a consistent modus operandi—posing as a credible businessman, securing high-value goods on deferred payment terms, and then disappearing after delivery while shutting down business operations.

Investigators suspect that forged business records, fake company credentials, and fabricated financial histories were used to build trust with suppliers and gain access to expensive raw materials.

Multi-State Surveillance Leads to Arrest in Surat

A special Crime Branch team tracked the accused through coordinated surveillance efforts across multiple cities, including Mumbai, Ahmedabad, and Surat. After nearly a month of technical monitoring and intelligence gathering, officials located and arrested him from a residential area in Surat.

Authorities also revealed that the accused had been involved in property-related activities while staying under the radar to avoid detection.

Growing Threat of Corporate Identity Fraud

The case highlights a rising trend of organised financial fraud targeting industries that rely heavily on trust-based transactions and deferred payments. Experts note that criminals increasingly exploit gaps in corporate verification systems by using fake GST registrations, temporary offices, and forged documentation to appear legitimate.

Cybercrime and financial fraud specialists warn that such schemes are becoming more complex with the widespread availability of digital business tools, making it easier to create convincing but fraudulent corporate identities.

Experts Urge Stronger Due Diligence in High-Value Transactions

Experts, including former IPS officer and cybercrime specialist Prof. Triveni Singh, emphasize the need for stricter verification procedures in commercial dealings. He noted that relying solely on paperwork or digital business profiles can expose companies to significant financial risk.

Authorities and industry experts recommend physical verification of business operations, bank account validation, and detailed background checks before engaging in high-value or deferred-payment transactions—particularly in sectors like pharmaceuticals, where single consignments can involve transactions worth crores.

Continue Reading

Business

EU Pressure Builds on Google as Regulators Face Calls for Massive Fine Over Search Practices

Published

on

By

A growing coalition of European industry groups is intensifying pressure on regulators to take decisive action against Google over allegations of unfair search practices that could reshape competition rules across the region’s digital economy.

Investigation Under Digital Markets Act Gains Momentum

The case is being examined by the European Commission under the European Union’s landmark Digital Markets Act (DMA), introduced to curb the dominance of major technology platforms and ensure fair competition.

Launched in March 2024, the investigation focuses on whether Google has been prioritising its own services in search results, potentially disadvantaging rival businesses that rely on online visibility to reach customers.

Industry Groups Demand Swift Action

Several prominent European organizations have jointly urged regulators to conclude the probe without further delay. They argue that prolonged investigations allow alleged anti-competitive practices to continue, putting European companies—especially startups—at a disadvantage.

Signatories include the European Publishers Council, the European Magazine Media Association, the European Tech Alliance, and EU Travel Tech.

In a joint statement, these groups warned that delays in enforcement are affecting innovation, profitability, and growth prospects for regional businesses competing in digital markets.

Google Denies Allegations

Google has rejected claims of bias, stating that its search algorithms are designed to deliver the most relevant and useful results to users. The company has also proposed adjustments to address regulatory concerns.

However, critics argue that these changes are insufficient and fail to address the core issue of market dominance.

Potential Billion-Euro Penalties

If found in violation of the DMA, Google could face significant financial penalties. Under EU rules, fines can reach a substantial percentage of a company’s global turnover, potentially amounting to billions of euros.

Regulators may also impose corrective measures requiring changes to business practices, which could have long-term implications for how digital platforms operate in Europe.

Wider Implications for Big Tech

The case highlights ongoing tensions between European regulators and major U.S. technology firms. In recent years, the EU has taken a more aggressive stance in enforcing competition laws, aiming to create a level playing field for local businesses.

A final ruling against Google could set a major precedent, influencing future enforcement actions and shaping the regulatory landscape for global tech companies operating within Europe.

As scrutiny intensifies, the outcome of the investigation is expected to play a critical role in defining the future of digital competition across the European Union.

Continue Reading

AI & Technology

Amazon Faces Potential Criminal Trial in Italy Over €1.2 Billion Tax Evasion Allegations

Published

on

By

Milan: U.S. tech giant Amazon is facing the prospect of a major legal showdown in Italy, after prosecutors in Milan formally requested a court to move forward with criminal proceedings over alleged tax evasion totaling approximately ₹12,500 crore (€1.2 billion).

The case targets Amazon’s European division along with four senior executives, marking one of the most significant tax-related investigations involving a global e-commerce platform in Europe.

Trial Push Despite Multi-Million Euro Settlement

The move comes even after Amazon reached a financial settlement with Italian tax authorities in December, agreeing to pay around ₹5,500 crore (€527 million), including interest, to resolve part of the dispute.

Typically, such settlements lead to the closure of criminal investigations. However, Milan prosecutors have opted to proceed, signaling a tougher stance on alleged corporate tax violations.

A preliminary hearing is expected in the coming months, where a judge will decide whether to formally indict the company and its executives or dismiss the case.

Allegations of VAT Evasion Through Marketplace Sellers

At the center of the investigation are claims that Amazon’s platform enabled non-European Union sellers to avoid paying value-added tax (VAT) on goods sold to Italian consumers between 2019 and 2021.

Prosecutors allege that the company’s marketplace structure allowed thousands of foreign vendors—many reportedly based in China—to operate without fully disclosing their identities or tax obligations. This, authorities argue, led to substantial VAT losses for the Italian government.

Under Italian law, online platforms facilitating sales can be held partially liable if third-party sellers fail to comply with tax requirements, a key point in the prosecution’s case.

Italian Government Named as Affected Party

In their filing, prosecutors identified Italy’s Economy Ministry as the injured party, citing significant financial damage resulting from the alleged tax evasion.

Legal experts say the outcome of the case could have wide-ranging implications across the European Union, where VAT systems are harmonized and similar compliance rules apply to digital marketplaces.

Multiple Investigations Add to Pressure

The VAT probe is just one of several legal challenges facing Amazon in Italy. The European Public Prosecutor’s Office is reportedly examining additional tax-related issues covering more recent years.

Meanwhile, Milan authorities are pursuing separate investigations into alleged customs fraud linked to imports from China and whether Amazon maintained an undeclared “permanent establishment” in Italy—potentially exposing it to higher tax liabilities.

In a separate regulatory action, Italy’s data protection authority recently ordered an Amazon unit to stop using personal data from over 1,800 employees at a warehouse near Rome.

Amazon Denies Allegations

Amazon has consistently denied wrongdoing and indicated it will strongly contest the allegations in court if the case proceeds. The company has also warned that prolonged legal uncertainty could impact investor confidence and Italy’s appeal as a destination for international business.

Broader Impact on Europe’s Digital Economy

If the case moves to trial, it could become a landmark moment for the regulation of global e-commerce platforms in Europe. Governments across the region are increasingly scrutinizing how digital marketplaces handle tax compliance, especially in cross-border transactions.

With online retail continuing to expand, regulators are under mounting pressure to ensure that multinational platforms and third-party sellers adhere to the same tax rules as traditional businesses.

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News